Skip to Main Content

Paper Details

Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation.
Clin Pharmacol Ther
1
2023
Author NameAffiliation
Judith C MaroHarvard Pilgrim Health Care Institute and Harvard Medical School
Michael NguyenCenter for Drug Evaluation and Research
Gerald J Dal PanCenter for Drug Evaluation and Research
Robert BallCenter for Drug Evaluation and Research
  • 1 - 4

Datasets

Release 1.2